Understanding Bone Marrow and Stem Cell Transplants for Acute Myeloid Leukemia (AML)

What is Acute Myeloid Leukemia (AML)?

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer that affects the blood and bone marrow. In individuals with AML, the bone marrow produces abnormal white blood cells, known as leukemia cells or blasts. These abnormal cells multiply uncontrollably, crowding out healthy red blood cells, white blood cells, and platelets. This imbalance can lead to various health complications.

Bone Marrow Transplant vs. Stem Cell Transplant

The terms 'bone marrow transplant' and 'stem cell transplant' (SCT) are often used interchangeably. A bone marrow transplant is a specific type of SCT. If the stem cells are collected from a donor's bloodstream instead of their bone marrow, the procedure might be referred to as a 'peripheral blood stem cell transplant'.

What are Stem Cell Transplants for AML?

Treatment for AML typically involves two main phases:

1. Induction: This phase uses chemotherapy (chemo) to reduce the number of leukemia cells in the body and achieve remission. Remission is generally defined as having less than 5% leukemia cells in the bone marrow, normal blood cell counts, and no signs or symptoms of AML.
2. Consolidation: Once remission is achieved, further treatment is administered to eliminate any remaining leukemia cells and help maintain remission.

For some individuals with AML, particularly those with intermediate- to high-risk disease who are in remission and can tolerate intensive treatment, an SCT may be recommended as part of the consolidation phase. The primary goal of an SCT is to restore a healthy bone marrow that is free from leukemia cells.

The Stem Cell Transplant Procedure

During an SCT, high doses of chemotherapy are administered to eliminate the existing cells in the bone marrow. Following this, an infusion of healthy stem cells is given. These healthy stem cells can be sourced from a donor's bone marrow (in a bone marrow transplant) or their blood (in a peripheral blood SCT).

The most common type of SCT used for AML is an allogeneic SCT, which involves using stem cells from a donor.

When is a Stem Cell Transplant Recommended for AML?

A bone marrow or stem cell transplant may be a beneficial treatment option for individuals with intermediate- to high-risk AML who have achieved remission and are capable of undergoing intensive treatment. It is a complex procedure with potential risks and benefits that are carefully considered by the medical team.

Minimal Residual Disease (MRD) and Relapse

Minimal Residual Disease (MRD) refers to the presence of a small number of leukemia cells that may remain in the body even after treatment. Studies have indicated that the presence of MRD before an SCT can be associated with an increased risk of AML returning (relapse) and potentially poorer survival outcomes.

Relapse after an SCT is a possibility in AML, with estimates suggesting that approximately 30% to 40% of individuals who undergo an SCT for AML may experience a relapse. Relapses often occur within the months following the transplant, with some research indicating a peak incidence between 3 to 6 months after the procedure.

Survival Rates and Transplant Outcomes

The overall 5-year survival rate for individuals diagnosed with AML is approximately 30.5%. However, an SCT can potentially improve survival rates. For instance, studies have shown that individuals treated with chemotherapy followed by an SCT had a 5-year survival rate of around 44.1%, compared to 37.8% for those who received chemotherapy alone.

It's important to acknowledge that SCTs are intensive treatments and can be associated with complications, including the risk of death. However, advancements in medical care have led to a significant decrease in transplant-related deaths over the past several decades.

Potential Long-Term Health Issues After SCT

Individuals who have undergone an SCT may face ongoing health challenges. Research suggests that those who received an allogeneic SCT for AML might be more likely to experience certain health problems compared to their matched sibling donors. These can include:

• Increased risk of developing other cancers.
• Chronic graft-versus-host disease (cGVHD), a condition where the donor's immune cells attack the recipient's body.
• Other long-term complications affecting various organ systems.

Long-Term Disease-Free Survival

For individuals who did not undergo an allogeneic SCT during their first remission, long-term outcomes can vary. Studies looking at 10-year outcomes have shown that a smaller percentage of patients remained disease-free compared to those who received a transplant. For example, among those younger than 60 years old, about 16.6% were disease-free at 10 years, while for those 60 years and older, this figure was around 2.4%.

When to Consult a Doctor

If you or a loved one has been diagnosed with AML, it is crucial to have an open and detailed discussion with your hematologist or oncologist about all available treatment options, including the potential role and risks of a stem cell transplant. Early consultation and understanding the nuances of AML treatment are vital for making informed decisions about your health journey.

Frequently Asked Questions (FAQ)

What is the main goal of a stem cell transplant for AML?

The main goal is to replace the diseased bone marrow with healthy stem cells that can produce normal blood cells, thereby eliminating leukemia cells and achieving long-term remission.

Is a stem cell transplant the only treatment for AML?

No, stem cell transplant is one of several treatment options for AML. Other treatments include chemotherapy, targeted therapy, and immunotherapy. The choice of treatment depends on the specific type of AML, the patient's age, overall health, and risk factors.

What are the risks associated with a stem cell transplant?

Risks include infection, graft-versus-host disease (GVHD), organ damage, infertility, and the possibility of relapse. However, medical advancements have significantly reduced these risks over time.

How long does recovery take after a stem cell transplant?

Recovery is a lengthy process that can take several months to a year or more. Patients require close monitoring and may need to make significant lifestyle adjustments during this period.

Can AML come back after a stem cell transplant?

Yes, AML can relapse after a stem cell transplant, although the transplant aims to minimize this risk. Close follow-up care is essential to detect and manage any signs of relapse early.